![Mendus AB (publ) logo](/logos/IMMU.ST.webp)
Mendus AB (publ)
SSE:IMMU.ST
Overview | Financials
Company Name | Mendus AB (publ) |
Symbol | IMMU.ST |
Currency | SEK |
Price | 0.469 |
Market Cap | 316,541,088 |
Dividend Yield | 0% |
52-week-range | 0.3 - 2.045 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Erik Manting Ph.D. |
Website | https://www.mendus.com |
An error occurred while fetching data.
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD